Drug intelligence / Profile preview

EVOCellic

Development stage: Preclinical
Lead developer: EVOMEDIS
Modality: Cell Therapies
Administration: Topical

Overview

EVOCellic is an allogeneic cell therapy developed by EVOMEDIS for the treatment of wounds, including chronic wounds and deep dermal burns. It consists of a tissue-engineered skin substitute composed of donor-derived (allogeneic) keratinocytes. These cells are preserved using a patented process and act as the active component by releasing essential growth factors and cytokines when applied to the wound site. This mechanism stimulates the skin's natural regeneration process and promotes faster, more effective healing. EVOCellic has received Orphan Drug Designation from the European Medicines Agency (EMA) for the treatment of partial deep dermal and full-thickness burns.

Brand names: EVOCellic
Other names: allogeneic keratinocyte-based tissue-engineered skin substitute

Beyond the preview

Go deeper on EVOCellic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVOCellic.

Explore the full profile